Pedro Blecua

Pedro Blecua

Auto-generated profile, based on publicly available information

Pedro Blecua

Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2019 in Science
Verified
Journal Article
Closed access
PDF file
RMRajarsi Mandal
Rajarsi Mandal
RSRobert M Samstein
Robert M Samstein
KLKen-Wing Lee
Ken-Wing Lee
JHJonathan J. Havel
Jonathan J. Havel
HWHao Wang
Hao Wang
TCTimothy A. Chan
Timothy A. Chan
High mutational load gets a response: Cancers harbor many genetic mutations. Defects in DNA mismatch repair prevent tumors from repairing certain types of DNA damage and lead to a hypermutable genomic state known as microsatellite instability (MSI). Some tumors with a high degree of MSI may be treatable with PD-1 (programmed cell death–1) immunotherapy, but patient response is highly variable. Mandal et al. studied drivers of differential response to immunotherapy in these patients and found that MSI intensity and insertion-deletion mutations strongly affected therapeutic outcome. Science , this issue p. 485

1 September 2014 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
DCDavid Chiron
David Chiron
MLMaurizio Di Liberto
Maurizio Di Liberto
PMPeter Martin
Peter Martin
XHXiangao Huang
Xiangao Huang
JSJeff Sharman
Jeff Sharman
SCSelina Chen-Kiang
Selina Chen-Kiang
Despite the unprecedented clinical activity of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib in mantle cell lymphoma (MCL), acquired resistance is common. By longitudinal integrative whole-exome and whole-transcriptome sequencing and targeted sequencing, we identified the first relapse-specific C481S mutation at the ibrutinib binding site of BTK in MCL cells at progression following a durable response. This mutation enhanced BTK and AKT activation and tissue-specific proliferation of resistant MCL cells driven by CDK4 activation. It was absent, however, in patients with primary resistance or progression following transient response to ibrutinib, suggesting alternative mechanisms of resistance. Through synergistic induction of PIK3IP1 and inhibition of PI3K–AKT activation, prolonged early G1 arrest induced by PD 0332991 (palbociclib) inhibition of CDK4 sensitized resistant lymphoma cells to ibrutinib killing when BTK was unmutated, and to PI3K inhibitors independent of C481S mutation. These data identify a genomic basis for acquired ibrutinib resistance in MCL and suggest a strategy to override both primary and acquired ibrutinib resistance. Significance: We have discovered the first relapse-specific BTK mutation in patients with MCL with acquired resistance, but not primary resistance, to ibrutinib, and demonstrated a rationale for targeting the proliferative resistant MCL cells by inhibiting CDK4 and the cell cycle in combination with ibrutinib in the presence of BTKWT or a PI3K inhibitor independent of BTK mutation. As drug resistance remains a major challenge and CDK4 and PI3K are dysregulated at a high frequency in human cancers, targeting CDK4 in genome-based combination therapy represents a novel approach to lymphoma and cancer therapy. Cancer Discov; 4(9); 1022–35. ©2014 AACR. This article is highlighted in the In This Issue feature, p. 973

11 October 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
NRNadeem Riaz
Nadeem Riaz
PBPedro Blecua
Pedro Blecua
RLRaymond S. Lim
Raymond S. Lim
RSRonglai Shen
Ronglai Shen
DHDaniel S Higginson
Daniel S Higginson
Jorge S. Reis-FilhoJorge S. Reis-Filho
Jorge S. Reis-Filho
BRCA1 and BRCA2 are involved in homologous recombination (HR) DNA repair and are germ-line cancer pre-disposition genes that result in a syndrome of hereditary breast and ovarian cancer (HBOC). Whether germ-line or somatic alterations in these genes or other members of the HR pathway and if mono- or bi-allelic alterations of HR-related genes have a phenotypic impact on other cancers remains to be fully elucidated. Here, we perform a pan-cancer analysis of The Cancer Genome Atlas (TCGA) data set and observe that bi-allelic pathogenic alterations in homologous recombination (HR) DNA repair-related genes are prevalent across many malignancies. These bi-allelic alterations often associate with genomic features of HR deficiency. Further, in ovarian, breast and prostate cancers, bi-allelic alterations are mutually exclusive of each other. The combination of these two properties facilitates reclassification of variants of unknown significance affecting DNA repair genes, and may help personalize HR directed therapies in the clinic.

16 November 2020 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
RSRobert M Samstein
Robert M Samstein
CKChirag Krishna
Chirag Krishna
XMXiaoxiao Ma
Xiaoxiao Ma
XPXin Pei
Xin Pei
KLKen-Wing Lee
Ken-Wing Lee
NRNadeem Riaz
Nadeem Riaz

8 May 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
FGFelipe C. Geyer
Felipe C. Geyer
ALAnqi Li
Anqi Li
APAnastasios D. Papanastasiou
Anastasios D. Papanastasiou
ASAlison Smith
Alison Smith
PSPier Selenica
Pier Selenica
Jorge S. Reis-FilhoJorge S. Reis-Filho
Jorge S. Reis-Filho
Adenomyoepithelioma of the breast is a rare tumor characterized by epithelial−myoepithelial differentiation, whose genetic underpinning is largely unknown. Here we show through whole-exome and targeted massively parallel sequencing analysis that whilst estrogen receptor (ER)-positive adenomyoepitheliomas display PIK3CA or AKT1 activating mutations, ER-negative adenomyoepitheliomas harbor highly recurrent codon Q61 HRAS hotspot mutations, which co-occur with PIK3CA or PIK3R1 mutations. In two- and three-dimensional cell culture models, forced expression of HRASQ61R in non-malignant ER-negative breast epithelial cells with or without a PIK3CAH1047R somatic knock-in results in transformation and the acquisition of the cardinal features of adenomyoepitheliomas, including the expression of myoepithelial markers, a reduction in E-cadherin expression, and an increase in AKT signaling. Our results demonstrate that adenomyoepitheliomas are genetically heterogeneous, and qualify mutations in HRAS, a gene whose mutations are vanishingly rare in common-type breast cancers, as likely drivers of ER-negative adenomyoepitheliomas.

30 August 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
FPFresia Pareja
Fresia Pareja
ABAlissa H. Brandes
Alissa H. Brandes
TBThais Basili
Thais Basili
PSPier Selenica
Pier Selenica
FGFelipe C. Geyer
Felipe C. Geyer
Jorge S. Reis-FilhoJorge S. Reis-Filho
Jorge S. Reis-Filho
Granular cell tumors (GCTs) are rare tumors that can arise in multiple anatomical locations, and are characterized by abundant intracytoplasmic granules. The genetic drivers of GCTs are currently unknown. Here, we apply whole-exome sequencing and targeted sequencing analysis to reveal mutually exclusive, clonal, inactivating somatic mutations in the endosomal pH regulatorsATP6AP1orATP6AP2in 72% of GCTs. Silencing of these genes in vitro results in impaired vesicle acidification, redistribution of endosomal compartments, and accumulation of intracytoplasmic granules, recapitulating the cardinal phenotypic characteristics of GCTs and providing a novel genotypic–phenotypic correlation. In addition, depletion of ATP6AP1 or ATP6AP2 results in the acquisition of oncogenic properties. Our results demonstrate that inactivating mutations ofATP6AP1andATP6AP2are likely oncogenic drivers of GCTs and underpin the genesis of the intracytoplasmic granules that characterize them, providing a genetic link between endosomal pH regulation and tumorigenesis.